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Obesity is a known risk factor for postmenopausal breast cancer, and is associated 
with worse disease prognosis in pre- and postmenopausal women. Adjuvant hormonal 
therapies improve disease prognosis in obese women, but many still recur. Given that 
obesity induces inflammation and increases levels of cyclooxygenase-2 (COX-2) 
enzyme, resulting in tumor proliferation, this retrospective study investigated if women 
on anti-inflammatory drugs would have improved disease outcomes by reduced 
production of prostaglandins by COX-2 pathway. Four hundred and forty women treated 
for invasive breast cancer in San Antonio clinics were included. Cases were classified as 
 viii 
NSAID users if notes included daily use of aspirin, ibuprofen, celecoxib or another COX-
2 inhibitor; patients were categorized as NSAID nonusers if they were not taking any 
NSAIDs, or if they used COX-2 drugs for pain as needed rather than daily. Patients on 
NSAIDs were more likely to be older, be slightly more obese and postmenopausal. 
NSAID and NSAID nonusers did not statistically significantly differ in regards to BMI 
categories, tumor stage, hormone receptor status, type of invasive tumor, ethnicity/race 
and type of surgery. NSAID users had significantly less recurrence rates compared to 
nonusers (p=0.05). Further, time to disease progression was delayed by almost 28 months 
in patients who were NSAIDs users. Although this trend was non-significant statistically 
due to low number of total recurrences, it is promising in the clinical setting. In a logistic 
regression model using NSAID use, BMI categories and hormonal therapy drug as 
independent variables to predict recurrence, use of NSAID was only statistically 
significant in the univariate model. Overweight women were more likely to develop 
recurrence than normal weight when holding NSAID use and endocrine therapy constant. 
Obese women had increase recurrence risk, but the trend was not statistically significant. 
Females using aromatase inhibitors were less likely to recur than those on tamoxifen. The 
results of this exploratory study had limited power to determine multiple modulating 
factors, but because they suggest a major clinical benefit, further analyses in a larger 
sample size are needed to confirm these findings.  
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Chapter 1:  Introduction 
Obesity is a significant public health problem not only in the United States but 
also worldwide. Over 35% of Americans are obese (1), and this percentage is alarming 
because obesity increases the risk of various cancers, including postmenopausal breast 
cancer (2). Obesity is also associated with worse disease prognosis in pre- and 
postmenopausal breast cancer patients (3, 4).  
Obesity is considered an inflamed state because of the secretion of adipokines and 
cytokines by the adipose tissue. These pro-inflammatory agents seem to be indirectly 
associated with decreased survival in obese breast cancer patients (5). While adjuvant 
hormonal therapy has helped increase the number of breast cancer survivors, many are 
still at risk of breast cancer recurrence, especially obese females (6, 7). Therapies to 
improve breast cancer patient outcome in conjunction with hormonal therapy need to be 
further explored.  
Daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 
(COX-2) inhibitors, such as aspirin, celecoxib and ibuprofen, have been associated with 
reduced risk of cancers, including breast cancer (8, 9). However, the data is limited and 
inconclusive regarding NSAIDs use and disease outcomes in breast cancer patients. This 
study aimed to enhance knowledge in breast cancer outcomes by analyzing whether the 
use of NSAIDs would decrease breast cancer recurrence rates in women treated with 
adjuvant hormonal therapy. 
The main hypothesis of this thesis was that breast cancer patients who use COX-2 
inhibitors on a daily basis have improved disease prognosis due to inhibition of COX-2-
derived prostaglandin E2 (PGE2) production. 
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Chapter 2:  Literature Review 
OBESITY AND BREAST CANCER  
Obesity has been a major public health issue in the United States for over 30 
years. Currently, more than one third of American adults are classified as obese (1), 
which is defined as body mass index (BMI) of or higher than 30kg/m
2 
(10). Obesity is a 
known risk of postmenopausal breast cancer (2, 11-13), and it is also related to worse 
disease outcomes in pre- and postmenopausal females (4, 5, 14-17).  
Findings of the Endogenous Hormones and Breast Cancer Collaborative Group 
showed that patients with BMIs between 27.5-29.9 kg/m
2
 had a 1.62-fold risk of breast 
cancer risk, and those with BMI ≥ 30 kg/m
2
 had a 1.36-fold increased risk when 
compared to women whose BMI were below 22.5 kg/m
2
, respectively (p=0.004) (2).  
The Million Women Study found that postmenopausal women had increased risk 
of breast cancer as BMI increased. Overweight and obese women had 1.21-fold (95% 
confidence interval [CI], 1.13-1.29) and 1.29-fold increase (95% CI, 1.22-1.36) in breast 
cancer incidence, respectively, compared to normal weight women (18). 
A large cohort with over 900,000 adults reported that risk of breast cancer 
mortality for women increased with each consecutive increase in BMI units. Females 
classified with obesity levels I, II and III
 
had risk of death increased by 1.63, 1.70 and 
2.12 times, respectively, when compared to females of normal weight (3).  
Similar evidence was observed in a study with more than 420,000 
postmenopausal females, which found that the risk of breast cancer death increased with 
increase in BMI, and that being overweight (BMI between 25.0 and 29.9kg/m
2
) and 
obese increased the rate ratio (RR) of breast cancer mortality by 1.33 and 1.60, 
respectively, in comparison to females of normal body weight (< 25kg/m
2
) (p < 0.0001) 
(17).  
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In regards to disease prognosis, a French cohort study with 14,709 breast cancer 
cases reported that obese women had worse disease outcome for metastasis recurrence in 
both univariate (hazard ratio [HR], 1.32; 95% CI, 1.19-1.48) and multivariate survival 
analysis (HR, 1.12; 95% CI, 1.00-1.26) compared to non-obese women (BMI was 
classified as below 30kg/m
2
) (12). 
Moreover, a prospective study that followed 923 women for 10 years after disease 
diagnosis found that 32% of non-obese women were at risk of recurrence compared to 
42% of obese women. Further, when only cases without lymph node metastases were 
examined, 19% non-obese patients developed recurrence compared to 32% of obese 
patients (19). Finally, a recent meta-analysis concluded that obese women had worse 
disease survival (HR, 1.33; 95%CI 1.21-1.47) than non-obese women (14). 
One of the mechanisms by which obesity is thought to promote a more aggressive 
disease in breast cancer patients is by the higher levels of local estrogen. Approximately 
60 to 75% of breast tumors are estrogen receptor (ER) positive (20-22), and obese 
postmenopausal women are more likely to develop ER-positive breast cancer (23, 24), 
suggesting their disease is driven by estrogen. After menopause, the adipose tissue is the 
main source of estrogen, which is produced by the conversion of androgens to estrogens 
by the enzyme aromatase (25).   
Two types of endocrine therapies are given to patients who have ER-positive 
breast tumors: tamoxifen and aromatase inhibitors (26, 27). Hormone-dependent breast 
cancers are typically associated with better clinical response to anti-estrogen therapies, 
but still 13% of stage III breast cancer patients are at risk of recurrence (28). 
Tamoxifen is the first line of endocrine therapy for premenopausal women, and 
was the only drug available to treat breast cancer between 1973 and 2000 (26). This drug 
is an example of a selective estrogen receptor modulator (SERM) because it works by 
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blocking estrogen from binding to its receptor in the breast tumor. Since estrogen acts as 
an agonist for the ER in the bone and uterine tissue, but as an antagonist in the breast, this 
drug prevents osteoporosis in women, but can increase risk of other gynecological 
cancers (29). 
Aromatase inhibitors are currently the most commonly used hormonal therapy 
among postmenopausal breast cancer patients (30, 31). These drugs suppress aromatase 





) and Letrozole (Femara
®
). 
Patients using aromatase inhibitors are prone to osteopenia and osteoporosis because the 
reduced levels of estrogen in the body reduce bone density (27).   
Few studies have analyzed the impact of BMI categories on endocrine therapy 
outcomes. Researchers of the Arimidex, Tamoxifen Alone or in Combination (ATAC) 
trial analyzed the influence of BMI on hormonal therapy efficacy. The analysis with 
5,172 postmenopausal breast cancer cases, who were estrogen receptor (ER) positive, 
concluded that females with a BMI above 35 kg/m
2
 had higher breast cancer recurrence 
rates compared to females with a BMI below 23 kg/m
2 
(HR, 1.39; 95% CI, 1.06-1.82) 
after treatment with hormonal therapies (7).  
Additionally, analysis of the BRENDA-cohort, a German retrospective study, 
showed that obese patients did worse on aromatase inhibitors in comparison to tamoxifen 
(32). Recent analysis with 6885 patients from three clinical trials also observed that obese 
women who were ER-positive and treated with endocrine therapy (aromatase inhibitors) 
and chemotherapy had poor disease outcomes. This trend is not seen in patients with 
other tumor cancer subtypes (6). 
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Multiple cancer-promoting pathways are activated in association with the obese 
state, including the Insulin-like Growth Factor-1 (IGF-1) and leptin pathways (33). 
Activation of the IGF-1, leptin and other growth factor pathways induce proliferation as 
well as survival signaling, most likely contributing to the lower response rates observed 
in the obese patient population to both endocrine as well as chemotherapy. However, 
recent data from our laboratory (unpublished) as well as from the Dannenberg group 
suggest that obese postmenopausal women may also fail treatment because of the 
inflammation caused by their obese state.  
 
OBESITY-INDUCED INFLAMMATION  
Adipose tissue is metabolically active and secretes adipokines, cytokines and 
hormone-like agents that contribute to inflammation (34). Studies have found that obese 
women produce more COX-2 enzyme than non-obese (35), which has been correlated 
with worse disease prognosis (36-39). PGE2 formed by COX-2 from arachidonic acid, 
increases aromatase activity (37), resulting in enhanced estrogen receptor activity, and, 
ultimately affecting tumor development (40) and growth. (41).  
Work by Dannenberg’s group showed that expression and activity of the enzyme 
aromatase were correlated with increased levels of COX-2 and PGE2 levels in the breast 
tissue of overweight and obese females at high risk of developing or who had breast 
cancer (35, 42). Preclinically, the authors found that release of fatty acids from 
adipocytes stimulated the synthesis of the inflammatory agent COX-2 by macrophages, 
which in turns leaded to PGE2 formation that upregulates activity of aromatase, estrogen 
receptor and impacts tumor growth (43). 
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Because COX-2 inhibitors suppress production of PGE2, it would be expected that 
use of NSAIDs would improve disease outcome in obese patients treated with aromatase 
inhibitors by decreasing inflammation and estrogen production that affect cell 
proliferation (Illustration 1). 
 
 
 Illustration 1: Proposed model of how the use of NSAIDs would 
be related to improved disease outcomes. Obesity increases COX-2 activity, which in 
turn produces PGE2 from arachidonic acids. PGE2 stimulates aromatase activity via 
cAMP pathway. Increased aromatase activity will produce more estrogen from androgens 
in the fat adipose cells. Higher estrogen synthesis in the adipocyte will also increase 
binding of estrogen in its receptor sites, thus leading to more tumor proliferation.  
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ANTI-INFLAMMATORY DRUGS AND BREAST CANCER 
The use of anti-inflammatory drugs to prevent cancer incidence is most well-
known in research with colorectal cancer (44-46). Numerous studies have investigated 
the association between NSAIDs and breast cancer incidence. A recent meta-analysis 
including 38 breast cancer studies concluded that the use of NSAIDs was associated with 
lower breast cancer risk (RR, 0.88; 95% CI, 0.64-0.97). Aspirin intake was also related to 
a decreased risk of the disease (RR, 0.87; 95% CI, 0.82-0.92) (9). However, the 
association remains inconclusive when breast cancer recurrence and/or survival are 
investigated.  
In the Life After Cancer Epidemiology (LACE) cohort conducted with 2,292 
survivors of breast cancer, the authors reported a negative and statistically significant 
association between breast cancer recurrence and regular ibuprofen use (RR, 0.56; 95% 
CI 0.32-0.98), which was defined as intake at least three days per week (47). Although 
the same association was not seen for aspirin alone (RR, 1.09; 95% CI, 0.74 to 1.61), 
when ibuprofen was taken combined with other non-aspirin NSAIDs, the risk of 
recurrence was reduced (RR, 0.56; 95% CI 0.33-0.95), but BMI did not account for 
differences.   
In a Nurse’s Health Study analysis, Holmes and colleagues investigated breast 
cancer recurrence in 4,164 cases diagnosed between 1976 and 2002. The authors 
concluded that current and frequent use of aspirin (6 to 7 days per week) was related to a 
statistically significant lower risk of breast cancer mortality (RR, 0.36; 95% CI, 0.24-
0.54). A decreased risk of distant recurrence (RR, 0.57; 95% CI, 0.39-0.82) compared to 
no aspirin use was also observed (48).  
The findings from the Iowa Women’s Health Study with 591 postmenopausal 
females indicated that any use of NSAIDs was associated with a lower risk of all causes 
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of mortality (HR, 0.57; 95% CI, 0.40-0.81). This trend was not observed for breast cancer 
death after adjustment for confounders (HR, 0.64; 95% CI, 0.39 to 1.05) (49). 
Li and collaborators reported that lifetime (categorized as more than 10 days per 
month) and current use of aspirin (categorized as more than 14 days per month) were not 
related to breast cancer survival in 1,024 women diagnosed between 1996 and 2001 (50). 
Regular recent use of ibuprofen decreased death of all causes, but the result was 
borderline significant after the model was adjusted for confounders (HR, 0.71; 95% CI, 
0.50-1.00). However, the use of NSAID was assessed only prior to breast cancer 
diagnosis, not after diagnosis.  
To our knowledge, no studies have analyzed the impact of NSAIDs on disease 
outcomes among overweight and obese patients treated with adjuvant hormonal therapy.  
 
CONCLUSION 
There is enough evidence to support that the use of anti-inflammatory drugs 
decreases breast cancer incidence. However, the data is inconsistent in regards to use of 
NSAIDs and breast cancer recurrence. This thesis aimed to investigate if the use of 
NSAIDs by breast cancer patients treated with endocrine therapy was associated with 
improved disease outcome. A secondary objective was to examine the influence of 






Chapter 3: Methods 
SUBJECTS  
This retrospective study included breast cancer female patients diagnosed with 
invasive breast cancer and whose records were available at the Cancer Therapy and 
Research Center at The University of Texas Health Science Center San Antonio. 
Patients’ charts from the clinics dated between 01/01/1987 and 31/12/2011 were 
reviewed to examine the association between NSAIDs use and breast cancer recurrence 
in women who were estrogen receptor (ER) positive and received hormonal therapy.  
Exclusion criteria included women with carcinoma in situ; who declined 
hormonal therapy or were non-compliant with drug treatment; patients whose therapies 
were unavailable from charts; patients who stopped using adjuvant therapy due to 
insurance issues or health problems; triple negative breast cancer cases; patients who had 
breast cancer metastasis at the time of diagnosis; patients whose dates of breast cancer 
diagnosis were not available.   
 
DESIGN 
This was an exploratory study that used retrospective data from patient charts to 
investigate if women classified as users of NSAIDs had better disease outcomes 
compared to nonusers when treated with adjuvant endocrine therapies. Informed consent 




DATA EXTRACTION AND CLASSIFICATION 
Information regarding demographics, tumor stage, estrogen and progesterone 
receptors, and medications were extracted from the patients charts. Weight at baseline 
was recorded, but when unavailable, the earliest weight that appeared on the charts was 
used. Premenopausal and perimenopausal women were grouped and classified as 
premenopausal because they receive tamoxifen as their first-line of hormonal therapy (26, 
51, 52).  
Women were classified as users of NSAIDs if follow-up or progress notes include 
daily use of aspirin, ibuprofen, celecoxib, naproxen, meloxican or another COX-2 
inhibitor in the list of medications. Patients whose medication list stated use of analgesics 
that do not inhibit production of PGE2 (53), such as acetaminophen and hydrocodone, as 
well as any COX-2 inhibitor used p.r.n. (as needed for pain) were considered NSAID 
nonusers.  
Recurrence was defined as any local, contralateral, distant tumor or metastasis of 
the primary breast cancer. Second primaries were not classified as recurrent breast 
cancer.   
 
STATISTICAL ANALYSIS 
The data was examined for normality. Duplicates were also analyzed to guarantee 
that one patient was not recorded twice in the event of referrals or having transferred 
medical care to the other clinic. Descriptive statistics (frequencies, means and standard 
deviations) were used to describe the data. Pearson’s chi-squared tests were used to 
analyze categorical variables (e.g., recurrence yes/no, postmenopausal vs. premenopausal 
status) of daily NSAID and NSAID nonusers. Student’s t-test were used to examine mean 
differences in numerical variables (e.g. BMI, time to recurrence). Wilcox non-parametric 
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test was used to examine if time to recurrence differed between NSAID users and 
nonusers that developed disease recurrence (44 patients). A priori confounding factors 
included were age at diagnosis and tumor stage. Logistic regression using odds ratios 
(OR) were used to predict recurrence (dichotomous yes/no). Significance level was set at 
p-value < 0.05, p-values were 2-sided and 95% CI. Statistical analyses were performed in 



















Chapter 4: Results and Discussion 
RESULTS 
Patient Characteristics 
This retrospective study consisted of 440 women diagnosed with invasive breast 
cancer who qualified to enter the study. Women whose hormonal therapy treatment and 
medications could not be obtained from the charts, those who did not seek treatment until 
the disease was already metastatic, who refused adjuvant therapy or were non-compliant 
with treatment were not included. Because underweight women might have higher risk of 
recurrence and/or decreased survival compared to those of normal weight (54-56), three 
underweight women were excluded from the analysis, not combined with normal weight 
patient group.  
Patients on NSAIDs were more likely to be older and postmenopausal (Table 1). 
NSAID and NSAID nonusers did not statistically significantly differ in regards to BMI 
categories, tumor stage, hormone receptor status, type of invasive tumor, ethnicity/race 
and type of surgery.  
NSAID users had lower recurrence rates compared to nonusers (p=0.05), with 
recurrence rates being reduced by half in NSAID users. Further, patients on NSAIDs 
remained free of recurrence for a longer time compared to those not on NSAIDs (50.6 
versus 78.5 months). This trend was non-significant statistically, but of relevance in the 
clinical setting. 
The majority of NSAID users and nonusers were ER positive and PR positive and 
had invasive ductal carcinoma breast cancer. Most NSAID users and nonusers were 
Hispanic and of White ethnicity.  
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More NSAID users were on aromatase inhibitors than NSAID nonusers 
(p<0.001).  Both NSAID users and non-users were more likely to have lumpectomies, 
followed by mastectomies and bilateral mastectomies.  
Aspirin was the most common type of anti-inflammatory drug among NSAID 
users. More NSAID nonusers had diabetes than NSAID users. Metformin was the main 
drug used to treat diabetes in this population.  
Although, in general, most patients did not use omega-3 fatty acids or statin, more 
NSAID users consumed omega-3 fatty acids and took statin drugs than nonusers. 
Before constructing logistic regression models, the distribution of patients by 
BMI categories by NSAID use and recurrence rates was analyzed. Table 2 shows the 
numbers and frequencies of how recurrence rates were affected by BMI and use of 
NSAID. Since the majority of the patients were overweight and obese rather than normal 
weight (385 compared to 75, respectively), the recurrence rates shown in Table 1 seem to 
have occurred mainly among overweight and obese breast cancer women. Overweight 
and obese NSAID users had approximately half recurrence rates as nonusers (6.7% 
versus 12.9%). 
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       Table 1 Descriptive characteristics of breast cancer cases (N=440) 
Characteristics NSAID nonusers (n=281)  NSAID users (n=159) p-value 
Age at diagnosis, years (mean ± SD) 55.5 ± 10.3 60.7 ± 10.7 < 0.001 
BMI, kg/m
2 
(mean ± SD) 30.7 ± 6.21 31.9 ± 6.70 0.072 
Time to recurrence, months (median)
a 
50.6 78.5 0.464 
 |----------------------------  N(%) ------------------------| χ
2





















































































Table 1 Descriptive characteristics of breast cancer cases (N=440) (continued) 
Characteristics Non-NSAID users (n=281)  NSAID users (n=159) χ
2





































































































Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation; BMI, body mass index; ER, estrogen 
receptor; PR, progesterone receptor. 
a 
Wilcox non-parametric test used to analyze time to recurrence analysis in 44 patients who had a recurrence  
b 
Other excision includes segmentectomy and quadrantectomy
 
c
 Calculations pertinent to the 159 patients classified as NSAID users
  
d 




























Table 2 Count of recurrence of normal weight versus overweight and obese NSAID users 
and nonusers (N=440) 
Characteristics NSAID nonusers (n=281)  NSAID users (n=159) 
 |--------------------------  N(%) ------------------------| 
Normal Weight (n=75) 
    Recurrence 







Overweight and Obese (n=365) 
    Recurrence 



















Analysis for prediction of recurrence 
In order to examine whether NSAID use predicted the dependent variable 
recurrence, five logistic regression models were created. The first model contained 
NSAID use as the only predictor. In the second model, NSAID use and three BMI 
categories (normal, overweight, obese) were inserted. The third model included NSAID 
use, BMI categories and type of hormonal therapy (Table 2). A fourth model was created 
with the predictors from model 3 and the independent variables diabetes status, omega-3 
fatty acids use and statin use were added because they were statistically significant 
different among NSAID users and nonusers, and these three factors have been thought to 
affect breast cancer risk and outcome. In the fifth model, the variables included were 
NSAID use, two BMI categories (normal versus overweight and obese) and endocrine 
therapy. Models using BMI as continuous variable were created, but data is not shown 
because the numerical variable was non-significant.  
 As seen in Table 2, in model 1, NSAID users were less likely to have breast 
cancer recurrence than nonusers (OR, 0.48; p-value=0.05). However, this difference was 
not significant after adjustment for age at diagnosis.  
The difference in use of NSAID was borderline significant when BMI categories 
were inserted in the model. However, NSAID use was non-significant in model 2 after 
age at diagnosis adjustment. When controlling for NSAID use and age at diagnosis, 
patients classified as overweight were 3 times as likely than normal weight patients to 
recur (p=0.04). When compared to obese patients, overweight females were 2 times as 
likely to have breast cancer recurrence (OR, 2.08; 95% CI, 1.06-4.14; data not shown), 
when NSAID use was held constant.  
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In model 3, NSAID users and nonusers did not differ in rates of recurrence when 
holding BMI categories and type of hormonal therapy constant. After adjustment for age, 
overweight patients were 3.36 times as likely to have breast cancer recurrence than 
normal weight patients, when controlling for NSAID use and endocrine therapy. Obese 
patients were 1.68 times are likely to recur compared to normal weight patients, but this 
trend was non-significant. Patients who used aromatase inhibitors were about half as 
likely (OR, 0.47; 95% CI, 0.23-0.94; p=0.03) to recur than those on tamoxifen, when 
holding NSAID use, BMI categories and age at diagnosis constant.  
In model 4, NSAID users had a trend of being less likely to have a recurrence, but 
the difference was still non-statistically significant when adjusting for confounders and 
when controlling for the remainder independent variables. Overweight patients were 3.30 
times as likely than normal patients to have a recurrence (95% CI, 1.10-12.3; p=0.04), 
when controlling for NSAID use and the other predictors and adjusting for age and tumor 
stage. Women using aromatase inhibitors were less likely to have a recurrence compared 
to those using tamoxifen (OR, 0.40; 95% CI, 0.18-0.83, p=0.01), when controlling for the 
other predictors and confounders. Diabetic patients were 2.57 times as likely to have a 
recurrence than non-diabetics (OR, 2.57; 95% CI, 1.15-5.76, p=0.02), when holding the 
other variables constant. Finally, the use of omega-3 fatty acids and statin drugs did not 
statistically significant predict recurrence when controlling for the other independent 
variables. 
In model 5, overweight and obese patients were 2.63 times as likely to have a 
recurrence than normal patients when controlling for the remainder predictors and 
confounders, but this trend was not statistically significant (95% CI, 0.95-9.44; p=0.09). 
Females using aromatase inhibitor use were less likely to develop a recurrence compared 
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to females using tamoxifen (OR, 0.40; 95% CI, 0.20-0.81, p=0.01), when holding NSAID 
use, BMI category, age at diagnosis and tumor stage constant. 
 21 




OR          95% CI            p-value 
Adjusted for age at diagnosis 
   OR           95% CI         p-value 
Adjusted for age
a
 and tumor stage 
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Aromatase inhibitor 
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    Diabetic status 
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    Omega-3 Use 
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     Statin Use 
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 Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; CI, confidence interval; BMI, body mass index 
a 
Adjustment for age at diagnosis 
Table 3 (continued) 
 23 
DISCUSSION 
In this exploratory study, NSAID patients were more likely to be older, 
postmenopausal and slightly obese compared to nonusers. This trend was also observed 
in the LACE cohort (47). NSAID users were approximately five years older than 
nonusers, but it is not anticipated that this had a significant impact on clinical outcome 
because disease prognosis is worse among younger women (57, 58). In contrary to 
younger age, higher age is linked with ER-positive breast tumors (59, 60). Because age at 
diagnosis could have been a confounding variable between NSAID use and recurrence, 
given that older women might use more analgesics to relieve joint pains, the created 
logistic regression models were adjusted for age.  
Results of ethnicity/race, tumor stage, hormone receptor status did not differ 
among NSAID users and nonusers, which contribute to reduced comparison bias. 
 In accordance with other three studies, NSAID users were less likely to develop 
breast cancer recurrence compared to NSAID nonusers. Holmes et al. (48) showed that 
current aspirin use (6 to 7 days per week) was associated with reduced risk of distant 
recurrence. Kwan and colleagues reported that ibuprofen alone decreased recurrence risk 
(RR, 0.96; 95% CI, 0.32-0.98), and that non-aspirin NSAID combined with ibuprofen 
also lowered risk of recurrence (RR, 0.56; 95% CI, 0.33-0.95) (47). In contrast, Li and 
colleagues did not found this association (50). However, only pre-diagnostic use of 
NSAIDs was analyzed, so it is unknown how use of NSAIDs after diagnosis of breast 
cancer may have impacted their disease prognosis.  
Breast cancer recurrences were reduced by half in NSAID users compared to 
nonusers in the chi-square analysis involving all patients. When the logistic regression 
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models were adjusted for age and tumor stage, NSAID use was associated with lower 
breast cancer recurrence, but this difference was no longer statistically significant.  
Approximately 25% of NSAID users were also taking omega-3 fatty acids 
compared to 11% of nonusers. This study lacked power to investigate if NSAID use in 
combination with omega-3 fatty acids added an extra benefit in reducing recurrence rates. 
Omega-3 fatty acids compete with arachidonic acid as substrates for enzymes that 
synthesize PGE2 and other pro-inflammatory agents (61). Therefore, it is likely that the 
concomitant use of NSAIDs and omega-3 fatty acids, at approved levels, might improve 
patient outcome by decreasing inflammation. The impact of statin drugs on breast 
recurrence is inconclusive (62). These drugs block the enzyme HMG-CoA reductase 
involved in biosynthesis of cholesterol, which decrease vascular inflammation (63), and 
could potentially work with NSAIDs to impact breast cancer prognosis.  
To date, no previous research has been conducted analyzing the time to disease 
progression in NSAID users and nonusers following invasive breast cancer diagnosis 
treated with endocrine therapy. Patients classified as NSAIDs nonusers had quicker time 
to recurrence at median time of 50.6 months compared to those on NSAIDs, who 
recurred at a median time of 78.5 months. The trend followed the direction expected, but 
it did not reach statistical significance. This is due to the small number of people who 
recurred (only 44 total had recurrence). But these results are encouraging for the clinical 
setting because patients using COX-2 inhibitor drugs remained disease-free for more than 
two years compared to those not on these drugs. 
This thesis work was more conservative in regards to NSAID type and frequency 
criteria. Patients who used acetaminophen and other analgesics that marginally block 
COX-2 pathway were categorized as NSAID nonusers different from other studies (47, 
50). Further, only daily use of COX-2 inhibitors fit the study definition of NSAID users, 
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while others have asked if patients used the drugs at least three days per week (47). 
Another factor that makes comparisons across studies more challenging is the lack of a 
standard definition of recurrence, especially because recurrence is easily misclassified 
(48).  
Given our population sample was mainly composed of overweight and obese 
women, recurrence rates predominantly occurred in these patients (data not shown). The 
small number of normal weight patients limited our comparison analysis. Across research 
studies, there is no consistent comparison of breast cancer risk, recurrence or survival 
across BMI categories. Findings are based on comparisons of BMI < 30 kg/m
2
 versus ≥ 
30 kg/m
2
 (12, 32), BMI < 25 kg/m
2
 versus ≥ 25 kg/m
2
 (50), BMI < 25 kg/m
2 
versus ≥ 30 
kg/m
2
 (64) or using tertiles or quartiles (7).  
Furthermore, it is unclear how overweight breast cancer patient with a BMI of 
29.50 kg/m
2
 and obese patient of BMI of 30.2 kg/m
2
 differ in their inflammatory status. 
Our findings showed that overweight women were more likely to recur compared to 
normal weight women. Obese women were also more prone to develop recurrence than 
normal weight, but this trend did not reach statistical significance. In fact, it has been 
suggested that crown-like structures in the breast of women may be a better biomarker of 
inflammation than BMI categories (42). 
Because of the small size, further comparisons by obesity levels (I, II and III) 
were not possible. Kwan et al. reported that morbidly obese women (BMI ≥ 40 kg/m
2
) 
were at higher risk of all causes of death (HR, 1.81; 95% CI, 1.42-2.32) and breast cancer 
mortality (HR, 1.40; 95% CI, 1.00-1.96) (56). Sestak and colleagues found that women 
with BMI above 35 kg/m
2
 had a righter rate of breast cancer recurrence than those with 
BMI < 23 kg/m
2
 (HR 1.39; p=0.03) (7). Subsequent analyses in a larger cohort are 
needed to compare recurrence across different obesity levels.  
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These results also confirmed that the use of aromatase inhibitors was associated 
with improved disease outcome in patients overall, as previously reported by Sestak (7) 
and Howell (65).  
Strengths of this study included height and weight measurements obtained at the 
clinics rather than self-reported; confirmation of use of anti-inflammatory drugs by 
examination of several progress notes; conservative definition of recurrence (excluding 
secondary primaries); inclusion of cases whose type of first line of endocrine therapy 
were available.  
Some of the limitations are the retrospective design; low power that resulted in 
wide confidence intervals; and reliance on BMI as measure of adiposity. BMI and body 
fat levels are correlated, but a biological marker of inflammation might help treatment of 
breast cancer patients. Due to reduced power, this study could not compare recurrence 
rates among normal weight versus overweight and obese women by NSAID use. 
Additionally, the majority of the patients were Hispanic, not primarily Whites/Caucasians 
(66-68). Therefore, the findings should be interpreted with caution and not generalizable 
to all breast cancer cases in the United States. The results of this exploratory study is in 
accordance with other reports that showed that breast cancer patients who use NSAIDs 






Chapter 5:  Conclusions 
In this specific population, mainly composed of overweight and obese breast 
cancer patients, recurrence rates were reduced to half among NSAID users. Equally as 
important, the use of COX-2 inhibitors delayed time to disease progression in women 
regardless of their BMI. Because of the low number of normal weight patients, further 
analysis are needed to investigate the benefit of NSAIDs among obese women compared 
to non-obese. Despite limited power, the evidence is suggestive of improved disease 
outcome in breast cancer patients. 
The majority of patients were Hispanic, followed by Whites. Thus, this study is 
not representative of the United States population. Further, few studies have been 
conducted with African-Americans, who mainly developed estrogen independent 
diseases. Research with African-American women who use NSAIDs may also increase 
knowledge on how these drugs impact disease prognosis. 
Future directions include a prospective study among women who use both 
NSAIDs and omega-3 fatty acids. These polyunsaturated fatty acids decrease 
inflammation by reducing synthesis of PGE2 (69), so it is important to investigate if 
patients using both drugs, at approved dosage, would have improved disease outcome.  
This was an exploratory study to analyze whether the use of anti-inflammatory 
drugs affected breast cancer prognosis in patients treated with endocrine therapies. 
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